Ibere Pharmaceuticals Class A (IBER) Peer Comparison
$10.18
$-0.03
(-0.29%)
As on 01-Mar-2023 15:58EDT
Market cap
$176 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
17.3
P/B Ratio
1.3
Div. Yield
0 %
Edit
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
Market cap ($ Mln) |
176 | 296 |
Revenue ($ Mln) |
-- | -- |
Net Profit ($ Mln) |
6.19 | -7.35 |
Net Margin (%) |
94.96 | -- |
RoE (%) |
4.69 | -- |
Price to Earnings |
17.25 | -- |
Price-To-Book |
1.30 | 4.18 |
Cashflow ($ Mln)
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
Cash From Operating Activities
|
-0.87 | -1.04 |
|
Cash Flow from Investing Activities
|
-138.00 | -300.00 |
|
Cash from Financing Activities
|
139.15 | 301.87 |
|
Net Cash Inflow / Outflow
|
-- | 0.82 |
Ratios
Profitability Ratios
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
ROCE (%)
|
2.45 | 3.42 |
|
ROE (%)
|
4.69 | 3.42 |
|
ROA (%)
|
4.44 | 3.12 |
|
EBIT Margin (%)
|
-- | -- |
|
Net Margin (%)
|
94.96 | 52.11 |
|
Cash Profit Margin (%)
|
-- | -- |
Growth Ratios
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
Revenue Growth (%)
|
-- | -- |
|
EBIT Growth (%)
|
-- | -- |
|
Net Profit Growth (%)
|
-- | 15,783.33 |
|
EPS Growth (%)
|
-- | 157.83 |
|
Book Value Growth (%)
|
4.88 | -- |
Valuation Ratios
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
Price / Earnings
|
18.67 | 77.31 |
|
Price / Book Value
|
0.23 | 1.32 |
|
Dividend Yield (%)
|
-- | -- |
|
EV/EBITDA
|
18.38 | 83,276.49 |
|
Market Cap ($ Cr)
|
-- | -- |
Solvency Ratios
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
Debt to Equity
|
0.00 | 9.95 |
|
Short term debt to equity ratio
|
0.00 | 9.95 |
|
Current Ratio
|
0.24 | 0.37 |
|
Quick Ratio
|
0.24 | -- |
|
Interest Coverage
|
65.02 | -0.21 |
Operating Efficiency Ratios
| Ibere Pharmaceuticals Class A (IBER) | Global Partner Acquisition II Corp (GPAC) | |
|---|---|---|
|
Debtors to sales (%)
|
-- | -- |
|
Asset Turnover
|
0.00 | 0.00 |
|
Receivable days
|
-- | -- |
|
Inventory Days
|
-- | -- |
|
Payable days
|
-- | -- |
|
Cash Conversion Cycle
|
-- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
